Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.
Also called NCT06925698
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 110 participants
- Sponsor
- Marmara University
- Registry
-
NCT06925698
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Türkiye
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06925698. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-30 (anticipated); primary completion 2027-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
- Acronym
- BETTER
- Condition
- Behcet Disease
- Condition
- Behcet Disease and Vascular Involvement
- Condition
- Deep Venous Thromboses
- Condition
- Post Thrombotic Syndrome
- Intervention (Drug)
- Placebo plus immunosuppression
- Intervention (Drug)
- Rivaroxaban plus immunosupression
- Lead sponsor
- Marmara University
- Collaborator
- Health Institutes of Turkey
Record details
- Record id
cardio:ct-nct06925698- Content hash
a485f690091e60c65bee22af12c318c52464dfa3ec4992d6c2ed48811a6b3139